Comments
Pharma major Dr Reddy’s Laboratories Ltd’s scrip zoomed 7.59 per cent on the Bombay Stock Exchange on Thursday after it announced the launch of a generic in US.
The scrip is trading at ₹2,821.85 on the Bombay Stock Exchange (BSE) by noon on Friday gaining 7.69 per cent over the previous close on Thursday.
The Hyderabad-based company launched Pyrimethamine Tablets, a therapeutic equivalent and first-wave generic version of Daraprim (pyrimethamine) Tablets in the US market. The product is the only AB-rated generic version Daraprim (pyrimethamine) Tablets approved by the USFDA.
The Daraprim (pyrimethamine) brand had U.S. sales of approximately $10 million for the most recent twelve months ending in January 2020, according to IQVIA Health.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.